Mass. company's newly approved treatment for deadly disease will cost $3.2M
Published
The first gene therapy for a deadly form of muscular dystrophy received preliminary U.S. approval on Thursday despite concerns from some government scientists about the treatment's ability to help boys with the inherited disease.The Food and Drug Administration approval provides a new option for…
#cambridge #sareptatherapeutics #hemophilia #fda #iv #petermarks #mda #lougehrigs #duchenne #sarepta